(IONS) Ionis Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IONS) Ionis Pharmaceuticals, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Ionis Pharmaceuticals, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to unlock the complete ready-to-use report.
Stars
TRYNGOLZA FCS
TRYNGOLZA fits the Star quadrant because Ionis launched it in 2024 for familial chylomicronemia syndrome, a disease affecting about 1 to 2 people per million. It is Ionis Pharmaceuticals, Inc.’s first wholly owned commercial cardiometabolic launch in years, so it gives the company direct control of price and growth. With premium orphan-drug pricing and very low competition, TRYNGOLZA should stay a Star by late 2025.
ApoC-III cardiometabolic expansion
Ionis is widening its apoC-III franchise beyond ultra-rare FCS into severe hypertriglyceridemia and mixed dyslipidemia, and that makes the growth pool far larger. In the Phase 3 BALANCE study, olezarsen cut triglycerides by 43% at 80 mg and 59% at 50 mg versus placebo, while the FDA approved it for FCS in 2024. That mix of a first launch plus a much bigger follow-on market gives it Star-like traits.
WAINUA hATTR-PN
WAINUA (eplontersen) fits the Stars bucket after its 2023 approval for hereditary transthyretin amyloidosis with polyneuropathy. Ionis and AstraZeneca co-develop it, which adds global reach, while rising ATTR diagnosis and broader treatment use keep demand in a high-growth lane.
SPINRAZA SMA
SPINRAZA, approved in 2016, is still a key spinal muscular atrophy therapy for infants, children, and adults. Its role stays strong because newborn screening keeps finding patients earlier, which supports long-term treatment starts and repeat use.
For Ionis Pharmaceuticals, Inc., the franchise remains strategically important in the BCG Matrix because demand is still durable, even in a competitive SMA market. In 2025, the asset continued to support a meaningful share of the company’s partner-driven value.
- Approved in 2016
- Used across ages
- Screening lifts diagnosis
- Still strategic for Ionis
QALSODY SOD1-ALS
QALSODY, approved in 2023, is the first therapy for SOD1-ALS, a rare subtype that affects about 2% of ALS patients. With no direct class rival and high unmet need, it fits Star status in Ionis Pharmaceuticals, Inc.’s BCG matrix. Orphan-disease pricing can support strong margins if uptake keeps growing.
- First-in-class SOD1-ALS therapy
- No direct class competitor
- Rare subtype, high unmet need
- Orphan pricing supports growth
Ionis Stars: TRYNGOLZA, WAINUA, SPINRAZA, and QALSODY Drive Growth
Ionis Pharmaceuticals, Inc.’s Stars are TRYNGOLZA, WAINUA, SPINRAZA, and QALSODY because each has clear growth support from recent launches, broadening labels, or rare-disease demand. TRYNGOLZA and WAINUA are the strongest growth drivers, while SPINRAZA and QALSODY keep durable, high-value demand. Together, they anchor Ionis Pharmaceuticals, Inc.’s BCG Matrix upside.
| Asset | Star signal |
|---|---|
| TRYNGOLZA | 2024 launch; first wholly owned growth asset |
What is included in the product
Detailed Word Document
Ionis BCG Matrix maps its drug pipeline by growth and share, highlighting where to invest, hold, or divest.
Editable Excel File
One-page BCG Matrix for Ionis Pharmaceuticals, Inc. that quickly spots winners, question marks, and cash traps.
Reference Sources
Lists trusted sources behind Ionis Pharmaceuticals, Inc. claims, making the analysis easier to verify, defend, and act on.
Cash Cows
SPINRAZA royalties
Biogen’s SPINRAZA sales were about $1.1 billion in 2024, and Ionis still earns tiered global royalties on that stream. Because SPINRAZA is a mature spinal muscular atrophy therapy with broad use, the royalty cash flow is steadier than a new launch. That makes it a classic Cash Cow in Ionis Pharmaceuticals, Inc.’s BCG mix.
QALSODY royalties
Biogen commercializes QALSODY, so Ionis Pharmaceuticals, Inc. gets a recurring royalty stream without carrying the full launch cost. The target pool is tiny: SOD1 ALS is about 1% to 2% of ALS cases, so spending needs stay limited. That makes QALSODY more of a cash generator than a cash sink.
WAINUA partner economics
WAINUA is partnered with AstraZeneca, so Ionis avoids the full launch spend and earns shared economics through royalties and milestones. AstraZeneca won U.S. FDA approval for WAINUA in December 2023, and the asset is now in the scale-up phase, where higher volume usually improves margin mix. That asset-light model is classic Cash Cow behavior once growth steadies.
Biogen collaboration cash flow
Ionis Pharmaceuticals, Inc.’s Biogen collaboration stays a steady cash cow: long-running deals bring royalties, milestones, and shared development funding from Spinraza-related programs and other partnered assets. That recurring cash helps support R&D and lowers pressure on Ionis’s own balance sheet.
Recurring royalties from Biogen
Milestone and cost-share funding
Supports pipeline spending
Mature licensing revenue
Mature licensing revenue is a Cash Cow for Ionis Pharmaceuticals, Inc. because partner deals with Bayer, Novartis, Roche, and Janssen bring steady cash without heavy sales costs. This lowers dependence on direct product sales and smooths funding for R&D. Stable partner cash remains one of Ionis Pharmaceuticals, Inc.'s core financial supports.
- Partner revenue diversifies cash flow
- Lower risk than product-only sales
- Supports research spend and operations
- Signals durable licensing value
Ionis’ Royalty Engine: SPINRAZA Fuels Low-Risk Growth
Ionis Pharmaceuticals, Inc. has a clear Cash Cow in SPINRAZA royalties: Biogen’s 2024 sales were about $1.1 billion, and Ionis still gets tiered global royalties. QALSODY and WAINUA add smaller but recurring partner cash, while Ionis avoids most launch spend. These streams help fund R&D with lower risk.
| Asset | Cash cow signal | Key data |
|---|---|---|
| SPINRAZA | Royalty engine | About $1.1B Biogen sales, 2024 |
| QALSODY | Recurring royalty | SOD1 ALS is about 1%-2% of ALS |
| WAINUA | Partnered cash | FDA approved Dec 2023 |
Preview the Actual Deliverable
Ionis Pharmaceuticals, Inc. Reference Sources
This preview of the Ionis Pharmaceuticals, Inc. BCG Matrix is the exact same document you’ll receive after purchase. No demo version or placeholder content—just the full, professionally formatted report ready for immediate use. Once purchased, the complete file is delivered to you exactly as shown here.
Dogs
TEGSEDI
TEGSEDI is a Dog in Ionis Pharmaceuticals, Inc.’s BCG Matrix: it is approved for hATTR polyneuropathy, but newer ATTR drugs have taken most demand. By late 2025, its share stayed very small and growth remained limited, so it has not become a major revenue driver. In BCG terms, this is a low-share, low-growth franchise with little expansion runway.
WAYLIVRA
WAYLIVRA sits in dog territory for Ionis Pharmaceuticals, Inc. It targets two ultra-rare diseases, familial chylomicronemia syndrome and familial partial lipodystrophy, where patient pools are tiny and uptake is limited. In Ionis Pharmaceuticals, Inc.'s 2025 reporting, WAYLIVRA still faced heavy competitive pressure, so growth and scale remain weak.
Volanesorsen legacy tail
Volanesorsen is a Dogs legacy tail for Ionis Pharmaceuticals, Inc.: it has been overtaken by newer apoC-III drugs, especially Tryngolza, which won U.S. approval in 2024. Remaining sales are confined to older markets and are not scaling. The tail is shrinking, not expanding, so it contributes little to 2025/2026 growth.
Inotersen legacy tail
Inotersen is Ionis Pharmaceuticals, Inc.'s older ATTR antisense therapy, and its role is now mostly legacy. Since WAINUA's 2024 launch, the commercial center has shifted to newer, better-positioned ATTR drugs, leaving inotersen with low growth and low share. That makes it a clear Dog in the BCG Matrix.
- Older ATTR product; legacy tail only
- WAINUA now drives the franchise
- Low growth, low share = Dog
Discontinued non-core programs
Ionis Pharmaceuticals, Inc. has steadily cut older, non-core programs that no longer justify more R&D spend. These exits fit the Dog bucket because the assets have limited share upside and weak return potential, so the company can redirect capital to programs with stronger launch economics. In 2025, that portfolio cleanup remained a clear capital-allocation choice.
- Drop low-value legacy assets
- Protect capital for stronger programs
- Reduce R&D drag on returns
These discontinued programs are not meant to compete for market share anymore; they are being removed from the lineup. That makes them classic Dogs in the BCG Matrix: low growth, low strategic fit, and no clear path to meaningful value creation.
Ionis Dogs: Legacy Rare-Disease Products With Tiny Growth
Dogs in Ionis Pharmaceuticals, Inc. are mostly legacy rare-disease products: TEGSEDI, WAYLIVRA, volanesorsen, and inotersen. They face tiny patient pools, weak growth, and newer rivals like WAINUA and Tryngolza, so they remain low-share, low-growth assets in 2025/2026.
| Asset | BCG | 2025/2026 status |
|---|---|---|
| TEGSEDI | Dog | Very small share |
| WAYLIVRA | Dog | Tiny market |
| Volanesorsen | Dog | Legacy tail |
Question Marks
Pelacarsen
Pelacarsen is Ionis Pharmaceuticals, Inc.'s Phase 3 antisense drug for patients with cardiovascular disease and elevated lipoprotein(a), or Lp(a). The HORIZON outcomes trial is enrolling about 8,000 patients, and the market could be huge because high Lp(a) affects roughly 1 in 5 adults worldwide. Until positive outcomes and approval, it stays a pure Question Mark.
Donidalorsen
Donidalorsen is still a Question Mark because it is in Phase 3 for hereditary angioedema and has not yet proven commercial demand. HAE is a specialist niche, affecting about 1 in 50,000 people, but it carries meaningful growth as newer prophylaxis wins share. If Ionis Pharmaceuticals, Inc. gets strong launch uptake, Donidalorsen could earn Star status; until then, the upside is still unproven.
ION363
ION363 sits in the Question Marks bucket for Ionis Pharmaceuticals, Inc. because it is in Phase 3 for amyotrophic lateral sclerosis, a disease with very high unmet need but tough trial risk and no clear late-stage success certainty. ALS affects about 30,000 people in the U.S. at a time, so the commercial upside can be meaningful if the study works. But the clinical bar is high, so the probability of failure still weighs on value.
Eplontersen cardiomyopathy
Eplontersen’s ATTR cardiomyopathy program is a classic Question Mark: it is still late stage, with the Phase 3 CARDIO-TTRansform study enrolling about 1,400 patients, but approval and payer uptake are not yet secured.
ATTR-CM is a fast-growing market, yet Ionis Pharmaceuticals, Inc. has no proven share here, so the asset still needs strong data, launch execution, and real-world adoption.
- Late-stage, high-upside, high-risk
- 1,400-patient Phase 3 program
- Market grows, share still unproven
Early renal-metabolic-ophthalmic pipeline
Ionis is still building early renal, metabolic, infectious, and ophthalmic programs, with more than 40 development candidates across its pipeline and little current market share in these niches. These assets are classic Question Marks in the BCG Matrix: they burn R&D cash now, but can scale into future Stars if late-stage data hit.
- Low share today
- High R&D spend today
- Optionality across 4 areas
- Potential future Star assets
Ionis’s Late-Stage Pipeline: Big Upside, Still Unproven
Ionis Pharmaceuticals, Inc.'s Question Marks are late-stage assets with big upside but no proven share yet. Pelacarsen, donidalorsen, ION363, and eplontersen each sit in Phase 3, so value depends on trial wins, approval, and launch uptake. The pipeline also includes more than 40 development candidates across renal, metabolic, infectious, and eye diseases.
| Asset | Stage | Why Question Mark |
|---|---|---|
| Pelacarsen | Phase 3 | 8,000-patient HORIZON trial; no approval yet |
| Donidalorsen | Phase 3 | HAE demand still unproven |
| ION363 | Phase 3 | ALS trial risk remains high |
| Eplontersen | Phase 3 | 1,400-patient CARDIO-TTRansform; share unproven |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.